H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Microbiology D-index 93 Citations 32,178 639 World Ranking 146 National Ranking 6
Medicine D-index 94 Citations 33,124 680 World Ranking 4888 National Ranking 207

Research.com Recognitions

Awards & Achievements

2011 - Fellow of the American Association for the Advancement of Science (AAAS)

2000 - Fellow of the Royal Society of Canada Academy of Science

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Virus
  • DNA

Mark A. Wainberg mainly investigates Virology, Reverse transcriptase, Virus, Molecular biology and Drug resistance. His research in Virology is mostly concerned with Viral replication. His work carried out in the field of Reverse transcriptase brings together such families of science as Nucleotidyltransferase, Mutant, Zidovudine and Primer.

His study focuses on the intersection of Virus and fields such as Amino acid with connections in the field of Capsid. The various areas that Mark A. Wainberg examines in his Molecular biology study include Cell culture, Transfection, RNA, DNA synthesis and Transcription. His Drug resistance research includes themes of Acquired immunodeficiency syndrome, Lentivirus, Viral load, Immunology and Genotype.

His most cited work include:

  • A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients: The INCAS Trial (687 citations)
  • High Rates of Forward Transmission Events after Acute/Early HIV-1 Infection (550 citations)
  • Public health implications of antiretroviral therapy and HIV drug resistance (465 citations)

What are the main themes of his work throughout his whole career to date?

Virology, Reverse transcriptase, Virus, Molecular biology and Drug resistance are his primary areas of study. His research on Virology focuses in particular on Viral replication. His study explores the link between Reverse transcriptase and topics such as Nevirapine that cross with problems in Efavirenz.

His Virus research includes elements of Cell culture and In vitro. The concepts of his Molecular biology study are interwoven with issues in RNA, Mutant, DNA, Enzyme and Primer binding site. His study in Drug resistance is interdisciplinary in nature, drawing from both Transmission, Viral load and Pharmacology, Drug.

He most often published in these fields:

  • Virology (91.54%)
  • Reverse transcriptase (44.10%)
  • Virus (41.87%)

What were the highlights of his more recent work (between 2012-2021)?

  • Virology (91.54%)
  • Dolutegravir (15.81%)
  • Integrase (18.71%)

In recent papers he was focusing on the following fields of study:

His main research concerns Virology, Dolutegravir, Integrase, Drug resistance and Raltegravir. His Virology research integrates issues from Mutation, Genetics and Reverse transcriptase. His research in Reverse transcriptase intersects with topics in Nevirapine, Molecular biology, Lamivudine and Rilpivirine.

His Dolutegravir study deals with Elvitegravir intersecting with Cabotegravir. The Integrase study combines topics in areas such as Integrase inhibitor and Resistance mutation. Within one scientific family, he focuses on topics pertaining to Viral load under Raltegravir, and may sometimes address concerns connected to Acquired immunodeficiency syndrome.

Between 2012 and 2021, his most popular works were:

  • Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study (200 citations)
  • CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. (146 citations)
  • CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. (146 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • DNA
  • Virus

Mark A. Wainberg focuses on Virology, Dolutegravir, Integrase, Drug resistance and Raltegravir. His Virology research is multidisciplinary, relying on both Mutation, Genetics and Resistance mutation. His Dolutegravir research incorporates themes from Integrase inhibitor, HIV drug resistance, Elvitegravir and Pharmacology.

His Integrase study incorporates themes from Reverse transcriptase and Binding site. Mark A. Wainberg has researched Drug resistance in several fields, including Regimen and Drug. He combines subjects such as Molecular biology, Antibody and In vivo with his study of Viral replication.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients: The INCAS Trial

Julio S. G. Montaner;Peter Reiss;David Cooper;Stefano Vella.
JAMA (1998)

974 Citations

High Rates of Forward Transmission Events after Acute/Early HIV-1 Infection

Bluma G Brenner;Michel Roger;Jean-Pierre Routy;Daniela Moisi.
The Journal of Infectious Diseases (2007)

807 Citations

Public health implications of antiretroviral therapy and HIV drug resistance

Mark A. Wainberg;Gerald Friedland.
JAMA (1998)

625 Citations

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.

C. A. B. Boucher;N. Cammack;P. Schipper;R. Schuurman.
Antimicrobial Agents and Chemotherapy (1993)

433 Citations

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.

Mark A. Wainberg;William C. Drosopoulos;Horacio Salomon;Mayla Hsu.
Science (1996)

383 Citations

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.

Bluma Brenner;Dan Turner;Maureen Oliveira;Daniela Moisi.
AIDS (2003)

349 Citations

In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Mark A Wainberg;Michael D Miller;Yudong Quan;Horacio Salomon.
Antiviral Therapy (1999)

346 Citations

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.

Qing Gao;Zhengxian Gu;M. A. Parniak;J. Cameron.
Antimicrobial Agents and Chemotherapy (1993)

312 Citations

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.

Janet M. Raboud;Julio S.G. Montaner;Brian Conway;Sandra Rae.
AIDS (1998)

311 Citations

Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance

Shalom Spira;Mark A Wainberg;Hugues Loemba;Dan Turner.
Journal of Antimicrobial Chemotherapy (2003)

300 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Mark A. Wainberg

Ben Berkhout

Ben Berkhout

University of Amsterdam

Publications: 99

Julio S. G. Montaner

Julio S. G. Montaner

University of British Columbia

Publications: 93

Douglas D. Richman

Douglas D. Richman

University of California, San Diego

Publications: 82

Michael D. Miller

Michael D. Miller

United States Military Academy

Publications: 77

Anne-Mieke Vandamme

Anne-Mieke Vandamme

Rega Institute for Medical Research

Publications: 76

Deenan Pillay

Deenan Pillay

University College London

Publications: 74

Raymond F. Schinazi

Raymond F. Schinazi

Emory University

Publications: 74

Robert W. Shafer

Robert W. Shafer

Stanford University

Publications: 72

Roland Marquet

Roland Marquet

University of Strasbourg

Publications: 69

Erik De Clercq

Erik De Clercq

Rega Institute for Medical Research

Publications: 68

Lawrence Kleiman

Lawrence Kleiman

McGill University

Publications: 67

Carlo Federico Perno

Carlo Federico Perno

University of Milan

Publications: 65

Charles A. Boucher

Charles A. Boucher

Erasmus University Rotterdam

Publications: 64

Vincent Soriano

Vincent Soriano

Hospital Universitario La Paz

Publications: 61

Robert S. Hogg

Robert S. Hogg

Simon Fraser University

Publications: 60

Hiroaki Mitsuya

Hiroaki Mitsuya

Kumamoto University

Publications: 59

Something went wrong. Please try again later.